David A. Siegel Protara Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

$42.5 Billion
Q1 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Protara Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 27,018 shares of TARA stock, worth $54,846. This represents 0.0% of its overall portfolio holdings.

Number of Shares

27,018

Previous 27,018 -0.0%

Holding current value

$54,846

Previous $50,000 116.0%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$1.12 - $1.93 $896 - $1,544	-800 Reduced 2.88%	27,018 $50,000
Q3 2023 Nov 14, 2023	SELL	$1.64 - $2.93 $5,740 - $10,255	-3,500 Reduced 11.18%	27,818 $46,000
Q2 2023 Aug 14, 2023	SELL	$2.27 - $3.59 $681 - $1,077	-300 Reduced 0.95%	31,318 $74,000
Q1 2023 May 15, 2023	SELL	$2.76 - $3.91 $43,056 - $60,996	-15,600 Reduced 33.04%	31,618 $98,000
Q4 2022 Feb 14, 2023	SELL	$2.43 - $3.7 $12,636 - $19,240	-5,200 Reduced 9.92%	47,218 $126,000

Q3 2022 Nov 14, 2022	SELL	$2.99 - $4.27 $2,093 - $2,988	-700 Reduced 1.32%	52,418 $155,000
Q2 2022 Aug 15, 2022	SELL	$2.8 - $5.33 $35,840 - $68,224	-12,800 Reduced 19.42%	53,118 $156,000
Q1 2022 May 16, 2022	SELL	$4.19 - $6.9 $439,950 - $724,500	-105,000 Reduced 61.43%	65,918 $337,000
Q4 2021 Feb 14, 2022	BUY	$6.15 - $7.76 $12,915 - $16,296	2,100 Added 1.24%	170,918 $1.15 Million
Q3 2021 Nov 15, 2021	BUY	$6.38 - $9.3 $704,990 - $1.03 Million	110,500 Added 189.48%	168,818 $1.17 Million
Q2 2021 Aug 16, 2021	BUY	$8.68 - $16.99 $401,016 - $784,937	46,200 Added 381.25%	58,318 $568,000
Q1 2021 May 17, 2021	SELL	$13.75 - $23.86 $101,750 - $176,564	-7,400 Reduced 37.91%	12,118 $191,000
Q4 2020 Feb 16, 2021	BUY	$16.97 - $25.34 $331,220 - $494,586	19,518 New	19,518 $473,000

Others Institutions Holding TARA

# of Institutions

Shares Held

4.55M

Call Options Held

102K

Put Options Held

18.2K

View Full List

About Protara Therapeutics, Inc.

Ticker TARA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 11,267,400
Market Cap $22.9M
Description
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chlorid...

More about TARA

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account